Resources Investment Advisors, Llc. Incyte Corp Transaction History

Resources Investment Advisors, Llc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$60.95 - $75.51 $256,111 - $317,293	-4,202 Reduced 49.75%	4,245 $264,000
Q1 2023 May 10, 2023	BUY	$70.23 - $86.01 $593,232 - $726,526	8,447 New	8,447 $610,000
Q3 2019 Nov 08, 2019	SELL	$72.82 - $86.52 $24,758 - $29,416	-340 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$73.52 - $88.7 $20,953 - $25,279	-285 Reduced 45.6%	340 $0
Q1 2019 May 10, 2019	SELL	$63.56 - $88.17 $27,203 - $37,736	-428 Reduced 40.65%	625 $0
Q4 2018 Feb 12, 2019	SELL	$58.5 - $69.94 $52,942 - $63,295	-905 Reduced 46.22%	1,053 $67,000
Q3 2018 Nov 07, 2018	BUY	$61.75 - $74.23 $13,585 - $16,330	220 Added 12.66%	1,958 $135,000
Q2 2018 Aug 15, 2018	BUY	$60.85 - $83.98 $51,174 - $70,627	841 Added 93.76%	1,738 $116,000
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $35,549 - $43,219	428 Added 91.26%	897 $75,000
Q4 2017 Jan 31, 2018	BUY	$93.56 - $116.6 $4,397 - $5,480	47 Added 11.14%	469 $44,000
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $43,223 - $54,754	396 Added 1523.08%	422 $49,000
Q2 2017 Aug 14, 2017	BUY	N/A	26	26 $3,000

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Resources Investment Advisors, Llc., based on Form 13F filings with the SEC.

Stay updated on Resources Investment Advisors, Llc. with notifications on news.